InflaRx N.V.
Status: Publicly traded
Direct answer
InflaRx N.V. is publicly traded on NASDAQ under the ticker IFRX.
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative,...
Can you invest in InflaRx N.V.?
Yes. InflaRx N.V. trades publicly on NASDAQ as IFRX.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for InflaRx N.V.
Detailed equity research is provided by MarketSnap.